Join Free For Buyer|Sign In

Professional Online Trade Platform for API, Preparation and Pharmaceutical Machinery and Equipment_EN-CPhI.cn

2019NEX

You are here:Home >> product >> Active Pharmaceutical Ingredients >> Other Active Pharmaceutical Ingredients >> Apixaban

Apixaban

Apixaban

Region: Jiangsu
Minimum Order Quantity:
Monthly Production Capacity:
Send Inquiry Add to Cart
Detailed Description
  • Main Sales Markets: North America, Central/South America, Western Europe, Eastern Europe, Australasia, Asia, Middle East, Africa
  • Sample Provided: no

Apixaban (BMS-562247-01, tradename Eliquis) is an anticoagulant for the treatment of venous thromboembolic events. It is a direct factor Xa inhibitor. Apixaban has been available in Europe since May 2012.[1] An FDA decision on apixaban which was expected on June 28, 2012 was initially delayed before final approval on December 28, 2012.[2][3] On August 21, 2014, Pfizer announced that apixaban was now FDA approved for treatment and secondary prophylaxis of deep vein thrombosis (DVT) and pulmonary embolism (PE).[4] It is being developed in a joint venture by Pfizer and Bristol-Myers Squibb.

Address: Taizhou,Jiangsu,China

City: Taizhou

Contact: Chen Bin

TEL: -523-86818997

Fax: -523-86818697

Send Inquiry
Previous Other Active Pharmaceutical Ingredients Next
Follow Us
CPhI Online Trade Platform: Worldwide|English|中国站
Customer Service:  86-400 610 1188 (9: 00-18: 00, Mon-Fri)
About Us| Contact Us| Terms of Services| Privacy Policy| Intellectual Property Statement| Links | Site Map
Copyright 2006-20 Shanghai UBM Sinoexpo International Exhibition Co Ltd (All Rights Reserved). ICP 05034851-53
网页对话
live chat